{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:27:16Z","timestamp":1792762036447,"version":"4.5.0"},"reference-count":33,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82502499"],"award-info":[{"award-number":["82502499"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Guangzhou Basic and Applied Basic Research Foundation","doi-asserted-by":"publisher","award":["2024A03J1157"],"award-info":[{"award-number":["2024A03J1157"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Guangzhou Basic and Applied Basic Research Foundation","doi-asserted-by":"publisher","award":["2024A03J1228"],"award-info":[{"award-number":["2024A03J1228"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bone metastases and associated skeletal-related events (SREs) severely compromise the survival and quality of life of patients with advanced cancer. Although bisphosphonates enable efficient bone targeting, their radiolabeled analogues exhibit limited uptake in osteolytic lesions due to the low hydroxyapatite content. Fibroblast activation protein, highly expressed in cancer-associated fibroblasts within the tumor microenvironment, provides tumor specificity and may enhance tracer accumulation in osteolytic bone metastases. To overcome this limitation, we developed two heterodimeric [68Ga]Ga\/[177Lu]Lu-DOTA-FAPI-bisphosphonate radioligands ([68Ga]Ga\/[177Lu]Lu-DFP-1\/2) by integrating a FAP-targeting moiety with a bisphosphonate backbone. Both compounds were synthesized with high radiochemical purity (&amp;gt;95%) and excellent in vitro stability. In A549-FAP xenograft models, dynamic PET\/CT imaging revealed comparable tumor uptake of [68Ga]Ga-DFP-1\/2 and [68Ga]Ga-FAPI-04 up to 2 h postinjection, with [68Ga]Ga-DFP-2 demonstrating faster clearance from nontarget organs. In tibial A549-FAP osteogenic models, [68Ga]Ga-DFP-2 showed significantly higher uptake (4.88 \u00b1 1.01% ID\/mL) than mono-FAP or monobisphosphonate tracers (p &amp;lt; 0.05). In osteolytic A549 models, [68Ga]Ga-DFP-2 uptake (3.16 \u00b1 0.82% ID\/mL) also exceeded that of monobisphosphonate tracers (p &amp;lt; 0.01). Biodistribution studies confirmed prolonged [177Lu]Lu-DFP-2 retention (26.94 \u00b1 4.40% ID\/g at 168 h). Collectively, these findings demonstrate that [68Ga]Ga\/[177Lu]Lu-DFP-2 possesses favorable dual bone- and tumor-targeting characteristics and holds strong translational promise as a novel theranostic agent for the imaging and treatment of lung cancer bone metastases.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.5c01617","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:40:16Z","timestamp":1777459216000},"page":"4037-4047","source":"Crossref","is-referenced-by-count":1,"title":["Development\nand Preclinical Evaluation of Dual-Target 68Ga\/177Lu-Labeled FAP-Bisphosphonate Radioligands\nwith Enhanced Osteoma Retention"],"prefix":"10.1021","volume":"23","author":[{"given":"Ruiyue","family":"Zhao","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou Medical University , , , ,","place":["Guangzhou, Guangdong, China, 510120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Deng","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou Medical University , , , ,","place":["Guangzhou, Guangdong, China, 510120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Jin","sequence":"additional","affiliation":[{"name":"Beijing Normal University , , ,","place":["Beijing, China, 100875"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingheng","family":"Xu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou Medical University , , , ,","place":["Guangzhou, Guangdong, China, 510120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanmei","family":"Liang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou Medical University , , , ,","place":["Guangzhou, Guangdong, China, 510120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4960-8570","authenticated-orcid":true,"given":"Shaoyu","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou Medical University , , , ,","place":["Guangzhou, Guangdong, China, 510120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Zhong","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou Medical University , , , ,","place":["Guangzhou, Guangdong, China, 510120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lv","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou Medical University , , , ,","place":["Guangzhou, Guangdong, China, 510120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxing","family":"He","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou Medical University , , ,","place":["Guangzhou, China, 510120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9530-8531","authenticated-orcid":true,"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou Medical University , , , ,","place":["Guangzhou, Guangdong, China, 510120"]},{"name":"Beijing Normal University , , ,","place":["Beijing, China, 100875"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1997-5687","authenticated-orcid":true,"given":"Xinlu","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou Medical University , , , ,","place":["Guangzhou, Guangdong, China, 510120"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"3","key":"2026080310013282600_cit1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1152\/physrev.00012.2019","article-title":"Bone metastasis: mechanisms,\ntherapies, and biomarkers","volume":"101","author":"Cle\u0301zardin","year":"2021","journal-title":"Physiol. Rev."},{"issue":"1","key":"2026080310013282600_cit2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/sj.cr.7290266","article-title":"Mechanisms\nof cancer metastasis to\nthe bone","volume":"15","author":"Yin","year":"2005","journal-title":"Cell Res."},{"issue":"1","key":"2026080310013282600_cit3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.21037\/tlcr-20-835","article-title":"Current progress\nand\nmechanisms of bone metastasis in lung cancer: a narrative review","volume":"10","author":"Wu","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"14","key":"2026080310013282600_cit4","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.7150\/ijbs.100960","article-title":"New insights into non-small\ncell lung cancer bone metastasis: mechanisms and therapies","volume":"20","author":"Xue","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"6","key":"2026080310013282600_cit5","first-page":"953","article-title":"Dosimetry of 188Re-hydroxyethylidene\ndiphosphonate in human prostate cancer skeletal metastases","volume":"44","author":"Liepe","year":"2003","journal-title":"J. Nucl. Med."},{"issue":"42","key":"2026080310013282600_cit6","doi-asserted-by":"publisher","first-page":"69014","DOI":"10.18632\/oncotarget.10883","article-title":"Samarium-153-EDTMP (Quadramet\u00ae)\nwith or without vaccine in metastatic castration-resistant prostate\ncancer: A randomized Phase 2 trial","volume":"7","author":"Heery","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"2026080310013282600_cit7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","article-title":"Targeted Alpha Therapy,\nan Emerging Class of Cancer Agents: A Review","volume":"4","author":"Parker","year":"2018","journal-title":"JAMA oncology"},{"issue":"7","key":"2026080310013282600_cit8","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1007\/s00520-019-05096-2","article-title":"The efficacy\nand safety of zoledronic acid and strontium-89 in treating non-small\ncell lung cancer: a systematic review and meta-analysis of randomized\ncontrolled trials","volume":"28","author":"Hu","year":"2020","journal-title":"Support. Care Cancer"},{"issue":"4","key":"2026080310013282600_cit9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10147-013-0597-7","article-title":"Strontium-89\n(Sr-89) chloride in the treatment of various cancer patients with\nmultiple bone metastases","volume":"19","author":"Zenda","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"2026080310013282600_cit10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fmed.2017.00046","article-title":"Comparative Therapeutic\nEfficacy of (153)Sm-EDTMP and (177)Lu-EDTMP for Bone Pain Palliation\nin Patients with Skeletal Metastases: Patients\u2019 Pain Score\nAnalysis and Personalized Dosimetry","volume":"4","author":"Sharma","year":"2017","journal-title":"Front.\nMed."},{"issue":"1","key":"2026080310013282600_cit11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13550-019-0566-x","article-title":"Biodistribution and post-therapy dosimetric analysis\nof [(177)Lu]Lu-DOTA(ZOL) in patients with osteoblastic metastases:\nfirst results","volume":"9","author":"Khawar","year":"2019","journal-title":"EJNMMI Res."},{"issue":"8","key":"2026080310013282600_cit12","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.2967\/jnumed.120.255851","article-title":"Evaluation of Safety\nand Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases","volume":"62","author":"Ferna\u0301ndez","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"6","key":"2026080310013282600_cit13","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1021\/acs.jmedchem.3c02372","article-title":"Theranostic\nAgent Targeting Bone Metastasis: A Novel [(68)Ga]Ga\/[(177)Lu]Lu-DOTA-HBED-bisphosphonate","volume":"67","author":"Jin","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"3","key":"2026080310013282600_cit14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera(\u00ae): The First FDA-\nand EMA-Approved Radiopharmaceutical\nfor Peptide Receptor Radionuclide Therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals\n(Basel)"},{"issue":"12","key":"2026080310013282600_cit15","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617\nfor Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"2026080310013282600_cit16","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action\nand role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"issue":"1050","key":"2026080310013282600_cit17","doi-asserted-by":"publisher","first-page":"20140752","DOI":"10.1259\/bjr.20140752","article-title":"(223)Ra\nand other bone-targeting radiopharmaceuticals-the\ntranslation of radiation biology into clinical practice","volume":"88","author":"Turner","year":"2015","journal-title":"Br. J. Radiol."},{"issue":"3","key":"2026080310013282600_cit18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00259-024-06942-0","article-title":"First-in-human\nstudy of dosimetry, safety and efficacy for [(177)Lu]Lu-P15\u2013073:\na novel bisphosphonate-based radioligand therapy (RLT) agent for bone\nmetastases","volume":"52","author":"Zhao","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"2026080310013282600_cit19","doi-asserted-by":"publisher","first-page":"21207","DOI":"10.1038\/s41598-020-78372-5","article-title":"Added value\nof hybrid SPECT with CT imaging for predicting poor therapeutic efficacy\nof (89)Sr in patients with bone metastasis","volume":"10","author":"Meng","year":"2020","journal-title":"Sci. Rep"},{"issue":"3","key":"2026080310013282600_cit20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12149-011-0560-5","article-title":"Effective\nuse of strontium-89 in osseous metastases","volume":"26","author":"Kuroda","year":"2012","journal-title":"Ann.\nNucl. Med."},{"issue":"17","key":"2026080310013282600_cit21","doi-asserted-by":"publisher","first-page":"12602","DOI":"10.1021\/acs.jmedchem.3c01294","article-title":"Lu-177-Labeled\nHetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide\nTherapy","volume":"66","author":"Zha","year":"2023","journal-title":"J. Med. Chem."},{"key":"2026080310013282600_cit22","doi-asserted-by":"publisher","first-page":"892147","DOI":"10.3389\/fnume.2022.892147","article-title":"DOTA Conjugate\nof Bisphosphonate and PSMA-Inhibitor: A Promising Combination for\nTherapy of Prostate Cancer Related Bone Metastases","volume":"2","author":"Grus","year":"2022","journal-title":"Front. Nucl. Med."},{"issue":"1","key":"2026080310013282600_cit23","article-title":"PSMA-Bisphosphonate\nImaging Agent: First Human Study of [68Ga]Ga-P17\u2013079 in Prostate\nCancer","volume":"66","author":"Wang","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"2","key":"2026080310013282600_cit24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting\ncancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat. Rev. Drug\nDiscov"},{"issue":"1","key":"2026080310013282600_cit25","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.2019194003","article-title":"(68)Ga FAPI PET\/CT:\nTracer Uptake in 28 Different Kinds\nof Cancer","volume":"1","author":"Hathi","year":"2019","journal-title":"Radiology. Imaging cancer"},{"key":"2026080310013282600_cit26","doi-asserted-by":"publisher","first-page":"111302","DOI":"10.1016\/j.ejrad.2024.111302","article-title":"Head-to-head comparison of [68Ga]Ga-FAPI PET and [18F]FDG PET in\nthe detection of bone and lymph node metastasis in various cancers:\nA systematic review and meta-analysis","volume":"171","author":"Wu","year":"2024","journal-title":"Eur.\nJ. Radiol."},{"issue":"2","key":"2026080310013282600_cit27","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222785","article-title":"FAPI Compared with\nFDG PET\/CT for Diagnosis of Primary and Metastatic Lung Cancer","volume":"308","author":"Wei","year":"2023","journal-title":"Radiology"},{"issue":"9","key":"2026080310013282600_cit28","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1097\/RLU.0000000000005297","article-title":"Efficacy and\nSafety Evaluation of 177Lu-FAP-2286 in the Treatment of Advanced Lung\nCancer","volume":"49","author":"Xie","year":"2024","journal-title":"Clin. Nucl. Med."},{"issue":"6","key":"2026080310013282600_cit29","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00259-021-05591-x","article-title":"Fatty acid-conjugated\nradiopharmaceuticals for fibroblast activation\nprotein-targeted radiotherapy","volume":"49","author":"Zhang","year":"2022","journal-title":"Eur. J. Nucl.\nMed. Mol. Imaging"},{"issue":"9","key":"2026080310013282600_cit30","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s00259-023-06211-6","article-title":"Fibroblast\nactivation protein targeted radiotherapy induces an immunogenic tumor\nmicroenvironment and enhances the efficacy of PD-1 immune checkpoint\ninhibition","volume":"50","author":"Zboralski","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"2026080310013282600_cit31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2141.2005.05444.x","article-title":"Molecular mechanisms\nof fibrinolysis","volume":"129","author":"Cesarman-Maus","year":"2005","journal-title":"Br. J. Hamaetol."},{"issue":"10","key":"2026080310013282600_cit32","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1359\/jbmr.060706","article-title":"Mixed metastatic\nlung cancer lesions in bone are inhibited by noggin overexpression\nand Rank:Fc administration","volume":"21","author":"Feeley","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"2026080310013282600_cit33","doi-asserted-by":"publisher","first-page":"1364311","DOI":"10.3389\/fonc.2024.1364311","article-title":"Comparison\nof the relative diagnostic performance of (68)Ga-DOTA-IBA and (18)F-NaF\nfor the detection of bone metastasis","volume":"14","author":"Deng","year":"2024","journal-title":"Front.\nOncol."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.5c01617","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4037\/66361177\/acs.molpharmaceut.5c01617.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4037\/66361177\/acs.molpharmaceut.5c01617.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:01:40Z","timestamp":1785765700000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/8\/4037\/5238658\/Development-and-Preclinical-Evaluation-of-Dual"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4,29]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c01617","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}